Sign In
Buy SNDX
$18.34
-0.0500 (-0.272%)
At Close: Jun 03, 2026
Wall Street Analysts Believe Syndax (SNDX) Could Rally 44%: Here's is How to Trade
02:55pm, Wednesday, 04'th Jan 2023 Zacks Investment Research
The mean of analysts' price targets for Syndax (SNDX) points to a 43.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Here's Why Momentum in Syndax (SNDX) Should Keep going
01:50pm, Wednesday, 04'th Jan 2023 Zacks Investment Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Syndax (SNDX) could be a great choice. It is one of the several stocks that passed through our "Recent Price St
VERA Dips Despite Positive Data From IgA Nephropathy Study
01:32pm, Wednesday, 04'th Jan 2023
VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.
Here's Why Momentum in Syndax (SNDX) Should Keep going
10:32am, Wednesday, 04'th Jan 2023
If you are looking for stocks that are well positioned to maintain their recent uptrend, Syndax (SNDX) could be a great choice. It is one of the several stocks that passed through our "Recent Price St
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
12:21pm, Tuesday, 03'rd Jan 2023 Zacks Investment Research
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.
Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout
02:35pm, Friday, 30'th Dec 2022 Zacks Investment Research
Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline bode well. Stiff competition in the target market remains a woe.
TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug
03:39pm, Thursday, 29'th Dec 2022 Zacks Investment Research
The FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch the drug in the first quarter of 2023. Stock up.
AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers
03:07pm, Thursday, 29'th Dec 2022 Zacks Investment Research
The Japanese Ministry of Health approves AstraZeneca's (AZN) Imfinzi plus Imjudo for treating advanced liver cancer and lung cancer.
Kala Pharmaceuticals (KALA) Up as FDA Accepts IND for KPI-012
04:13pm, Wednesday, 28'th Dec 2022 Zacks Investment Research
The FDA accepts Kala Pharmaceuticals' (KALA) investigational new drug application for pipeline candidate KPI-012 for treating persistent corneal epithelial defect. Stock up.
ACER Down Despite FDA Nod for Urea Cycle Disorders Drug
02:28pm, Wednesday, 28'th Dec 2022 Zacks Investment Research
The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.
Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals
12:15pm, Wednesday, 28'th Dec 2022 Zacks Investment Research
Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article.
ACER Down Despite FDA Nod for Urea Cycle Disorders Drug
10:51am, Wednesday, 28'th Dec 2022
The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.
4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023
04:21pm, Tuesday, 27'th Dec 2022 Zacks Investment Research
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR
Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive
03:36pm, Tuesday, 27'th Dec 2022 Zacks Investment Research
One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.
4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023
12:47pm, Tuesday, 27'th Dec 2022
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR
